Opendata, web and dolomites

TOL2

An effective and safe targeted therapy for treatment of Myasthenia gravis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TOL2 project word cloud

Explore the words cloud of the TOL2 project. It provides you a very rough idea of what is the project "TOL2" about.

diseases    intrinsic    causes    wacc    trials    people    20    toleranzia    14    gravis    tol2    therapy    participation    total    quality    npv    treatments    breathing    weakness    progress    arms    immune    unemployment    crisis    257m    patients    clinical    pharma    sight    drug    medical    myasthenia    life    considering    skeletal    responsible    look    muscles    2019    moving    utilize    granted    urgent    chronic    designation    symptomatic    co    fda    myasthenic    though    innovative    payments    neuromuscular    mg    orphan    therapies    body    iia    streams    restricts    calculated    tolerance    complete    treat    patient    swedish    expensive    pharmaceutical    autoimmune    disease    reducing    treatment    model    royalties    parts    strategy    everyday    revenue    full    surpass    10    frequently    sales    legs    death    global    business    2021    2029    upfront    crises    milestone    company    power    cure    induces    first    mission    remission    rare    investment   

Project "TOL2" data sheet

The following table provides information about the project.

Coordinator
TOLERANZIA AB 

Organization address
address: ERIK DAHLBERGSGATAN 11 A
city: GOTEBORG
postcode: 411 26
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.toleranzia.com/program/sme-instrument-phase-1-project/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TOLERANZIA AB SE (GOTEBORG) coordinator 50˙000.00

Map

 Project objective

Myasthenia gravis (MG) is a rare disease affecting 2/10.000 people. Although being a rare disease, MG is the most common chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs. MG restricts patients from having a full participation in everyday activities, frequently leading to unemployment and reducing their quality of life. Many patients may eventually experience a myasthenic crisis, the treatment of which is very expensive. Such crises can lead to the death of the patient. There is currently no cure for MG and neither is there any cure in sight. Even though there are over 30 MG-related clinical trials currently in progress, most of them are only symptomatic treatments.

Considering this urgent medical need, we are developing TOL2, an innovative therapy with potential to cure MG (not only symptomatic treatment). This will be the first therapy for MG that induces long-term remission. TOL2 is based on a tolerance-technology with potential to be developed for treatment of other autoimmune diseases. TOL2 has been granted Orphan Drug Designation by the US FDA.

Toleranzia is a Swedish pharmaceutical research and development company. Our therapies utilize the immune system’s own intrinsic power to treat autoimmune diseases. Our mission is to develop innovative therapies that will cure autoimmune diseases.

Our business strategy for TOL2 is to complete clinical phase IIa, and then to look for an agreement with a global pharma partner, who can or co-develop the therapy. Under this business model, revenue streams are obtained through upfront payments, milestone payments and royalties on product sales.

Considering total project cost of €5,6 m during years 2019-2021, upfront payments above €14 m and 20% royalties over sales, the NPV of the investment calculated (WACC 10%) will surpass €257m by 2029.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOL2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOL2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More